drugset
drugset / Trial / NCT05976373

A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.

NCT05976373 ↗

Phase 1 Completed 38 enrolled Sanofi Regeneron Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 1, single subcutaneous dose study to evaluate safety and pharmacokinetic of 2 different dupilumab drug products in adult healthy volunteers. The duration per participant is up to 11 weeks.

Timeline

Start
2015-01-05
Primary completion
2015-03-30
Completion
2015-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody — Subcutaneous

Indications

No indication recorded.